Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma

Detalles Bibliográficos
Autores principales: Shackleton, Louisa, Fay, James, Smyth, Elizabeth, Murphy, Philip, Glavey, Siobhan, Quinn, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176006/
https://www.ncbi.nlm.nih.gov/pubmed/35847740
http://dx.doi.org/10.1002/jha2.34
_version_ 1784722570140975104
author Shackleton, Louisa
Fay, James
Smyth, Elizabeth
Murphy, Philip
Glavey, Siobhan
Quinn, John
author_facet Shackleton, Louisa
Fay, James
Smyth, Elizabeth
Murphy, Philip
Glavey, Siobhan
Quinn, John
author_sort Shackleton, Louisa
collection PubMed
description
format Online
Article
Text
id pubmed-9176006
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91760062022-07-14 Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma Shackleton, Louisa Fay, James Smyth, Elizabeth Murphy, Philip Glavey, Siobhan Quinn, John EJHaem Case Reports John Wiley and Sons Inc. 2020-07-04 /pmc/articles/PMC9176006/ /pubmed/35847740 http://dx.doi.org/10.1002/jha2.34 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Shackleton, Louisa
Fay, James
Smyth, Elizabeth
Murphy, Philip
Glavey, Siobhan
Quinn, John
Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title_full Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title_fullStr Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title_full_unstemmed Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title_short Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
title_sort laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176006/
https://www.ncbi.nlm.nih.gov/pubmed/35847740
http://dx.doi.org/10.1002/jha2.34
work_keys_str_mv AT shackletonlouisa laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma
AT fayjames laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma
AT smythelizabeth laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma
AT murphyphilip laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma
AT glaveysiobhan laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma
AT quinnjohn laboratoryfeaturesoftumourlysissyndromefollowingdaratumumabmonotherapyinrelapsedrefractorymultiplemyeloma

Ejemplares similares